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Abstract
Objective
The Systemic Synuclein Sampling Study (S4) measured α-synuclein in multiple tissues and
biofluids within the same patients with Parkinson disease (PD) vs healthy controls (HCs).
Methods
S4 was a 6-site cross-sectional observational study of participants with early, moderate, or
advanced PD and HCs. Motor and nonmotor measures and dopamine transporter SPECT
were obtained. Biopsies of skin, colon, submandibular gland (SMG), CSF, saliva, and blood
were collected. Tissue biopsy sections were stained with 5C12 monoclonal antibody against
pathologic α-synuclein; digital images were interpreted by neuropathologists blinded to di-
agnosis. Biofluid total α-synuclein was quantified using ELISA.
Results
The final cohort included 59 patients with PD and 21 HCs. CSF α-synuclein was lower in
patients with PD vs HCs; sensitivity/specificity of CSF α-synuclein for PD diagnosis was
87.0%/63.2%, respectively. Sensitivity of α-synuclein immunoreactivity for PD diagnosis was
56.1% for SMG and 24.1% for skin; specificity was 92.9% and 100%, respectively. There were
no significant relationships between different measures of α-synuclein within participants.
Conclusions
S4 confirms lower total α-synuclein levels in CSF in patients with PD compared to HCs, but
specificity is low. In contrast, α-synuclein immunoreactivity in skin and SMG is specific for PD
but sensitivity is low. Relationships within participants across different tissues and biofluids
could not be demonstrated. Measures of pathologic forms of α-synuclein with higher accuracy
are critically needed.
Classification of evidence
This study provides Class III evidence that total CSF α-synuclein does not accurately distin-
guish patients with PD from HCs, and that monoclonal antibody staining for SMG and skin
total α-synuclein is specific but not sensitive for PD diagnosis.
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Parkinson disease (PD) accounts for a large proportion of
the global burden of disease.1 Many clinical trials in PD
have failed to identify disease-modifying therapies.2 To
have a meaningful impact, intervention likely must occur in
the earliest stages of pathology.3 Accurate PD biomarkers
are needed to enable early diagnosis, test for target en-
gagement, and serve as surrogate measures of disease in
clinical trials.
α-Synuclein is a lead candidate PD biomarker based on its
key role in PD pathophysiology. Studies show tremendous
overlap between patients with PD and healthy controls
(HCs) in total α-synuclein values in biofluids,4,5 likely due
to various factors.6 There are, in addition, conflicting re-
ports on occurrence of pathologic α-synuclein in peripheral
tissue in PD,7–9 attributable to methodologic factors in-
cluding specimen acquisition/processing, α-synuclein staining
methods, and neuropathologist expertise and blinding.9
Studying the distribution of α-synuclein across the central
and peripheral nervous system in vivo in patients with PD
alongside HCs contributes to our understanding of PD
pathophysiology, distribution of α-synuclein pathology, and
disease progression.
The Systemic Synuclein Sampling Study (S4) assessed key
gaps in knowledge by comparing interindividual and intra-
individual total α-synuclein in CSF and peripheral (blood,
saliva) fluid compartments, and the occurrence of immu-
nohistochemically defined α-synuclein pathology in 3 pe-
ripheral tissues (colon, skin, and submandibular gland
[SMG]) at different PD stages compared to HCs. Analyzing
biofluids and tissue, we tested 2 main hypotheses: that (1)
α-synuclein biomarkers in CSF and SMG have the highest
sensitivity and specificity for PD diagnosis and (2) there are
significant relationships among within-subject measures of
α-synuclein.
Methods
The full S4 protocol is available at michaeljfox.org/files/S4_
Clinical_Study_Protocol_Version_2.pdf.
The primary research questions addressed in this study were
as follows:
1. What is the diagnostic accuracy of total α-synuclein in
CSF, serum, plasma, whole blood, and saliva as an in vivo PD
biomarker?
2. What is the prevalence of positive staining for pathologic
α-synuclein in skin, SMG, and colon in patients with PD vs
HCs and what is its diagnostic accuracy in each of these
tissues as a PD biomarker?
3. What is the intraindividual, i.e., within-subject, relation-
ship between α-synuclein in tissues and biofluids?
The design of this study provides Class III evidence for
questions 1 and 2 and Class IV evidence for question 3.
Participants
S4, a cross-sectional observational study, enrolled participants
from October 2015 to August 2017 at 6 sites in North America.
As previously described,10–12 the study aimed to recruit 60 in-
dividuals with a diagnosis of idiopathic PD. Enrollment criteria
were (1) age ≥40 years; (2) clinical diagnosis of PD, requiring
presence of bradykinesia plus either rest tremor or rigidity; (3)
decreased dopamine transporter (DAT) binding on SPECT
(based on age-matched normative data); and (4) classification
into 1 of 3 groups of disease severity: early PD (≤2 years since
diagnosis, not treated with dopaminergic medication), moder-
ate PD (2–5 years since diagnosis treated with dopaminergic
medication but without motor fluctuations), and advanced PD
(≥5 years since diagnosis, with motor fluctuations).
Twenty-one HCs, with normal DAT SPECT, were also
recruited. In both groups, exclusion criteria were clinical di-
agnosis of dementia based on the site investigator’s de-
termination and comorbid medical conditions precluding
specimen acquisition, as described.12
Standard protocol approvals, registrations,
and patient consents
The study was performed in accordance with the Declaration
of Helsinki. Written informed consent was provided by all
participants. Institutional review board approval was obtained
at each study site.
Assessments
Clinical assessments, imaging, and biospecimen acquisition
occurred as follows:
Clinical/imaging assessments:
1. Demographics
2. Medical/neurologic history and medications
3. Motor assessments: Movement Disorders Society Uni-
fied Parkinson’s Disease Rating Scale (MDS-UPDRS)
part III and IV and Hoehn & Yahr stage
Glossary
CI = confidence interval; DAT = dopamine transporter; GI = gastrointestinal; HC = healthy control; MDS-UPDRS =
Movement Disorders Society Unified Parkinson’s Disease Rating Scale; pRBD = possible REM sleep behavior disorder;
PD = Parkinson disease; S4 = Systemic Synuclein Sampling Study; SBR = specific binding ratio; SMG = submandibular
gland; SOP = standard operating procedure.
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4. Nonmotor assessments: neuropsychiatric symptoms
were assessed with the MDS-UPDRS I and the Montreal
Cognitive Assessment13; autonomic symptoms were
assessed with the Scales for Outcomes in Parkinson’s
Disease–Autonomic14; presence of possible REM sleep
behavior disorder (pRBD) was ascertained via review of
study medical history and medication logs, which in turn
reflected information obtained by the site investigator via
patient interview. Participants were classified as having
pRBD if they were listed as having RBD on the medical
condition log or if RBD was listed as an indication for a
medication on the medication log.
5. Functional status: Modified Schwab and England
Activities of Daily Living Scale and MDS-UPDRS part II
6. Olfaction was assessed with the University of Pennsylva-
nia Smell Identification test: participants were classified
as normosmic, hyposmic, or anosmic based on normative
data accounting for age and sex15
7. DAT SPECT: mean striatal specific binding ratio (SBR)
calculated as average of putamen and caudate SBR on
right and left
Biofluid and peripheral tissue collection and
α-synuclein detection
Procedures for collection of specimens and analysis for
α-synuclein and hemoglobin are detailed in the S4 biologics
manual16 and described in previous publications.10,12 Briefly,
biofluids collected included CSF, blood, and saliva. Total
α-synuclein was measured using a commercially available
ELISA.10 Specimens with hemoglobin levels considered to be
high enough to affect α-synuclein measures were excluded
from analyses (200 ng/mL for CSF, saliva, and serum and 35
ng/mL for plasma4,17). To further account for possible in-
fluence of hemoglobin on α-synuclein levels in serum and
plasma, we explored α-synuclein/hemoglobin ratio.4
Biopsies of skin, sigmoid colon, and SMG were obtained as
described.10–12,16 Briefly, two 3-mm skin punch biopsies
were obtained from the paravertebral posterior–inferior
cervical area and 2 from the mid-thigh. Up to 8 colon bi-
opsies were obtained via flexible sigmoidoscopy, and up to 5
SMG biopsies were obtained using a 16-gauge core biopsy
instrument. Biopsies were processed as described.10,16 Four
slides spaced equidistantly in each cassette were stained with
hematoxylin & eosin to assess for the presence of adequate
tissue, defined by ≥1 fragment(s) of a given tissue type
containing a minimal aggregate amount (2 mm2) of target
tissue. Target tissue was defined as glandular tissue (epi-
thelial secretory acini and intervening stroma) for SMG,
submucosa for colon, and dermis for skin.
Three slides from each cassette (each containing 2–3 biopsy
fragments) were subjected to a protease, which removes
nonpathologic forms of α-synuclein, then stained with the
mouse monoclonal immunoglobulin 5C12 antibody as
described.10,11 The immunohistochemical staining method
applied in S4 was chosen after a rigorous, blinded comparison
of multiple protocols available at the time of initiation of S4,
using gold standard autopsy-confirmed peripheral tissue
samples, as described.11 Images of stained slides were dis-
tributed to 3 independent neuropathologists blinded to
diagnostic group. Neuropathologist ratings were used to
classify each slide as positive or negative for α-synuclein
pathology, as defined morphologically during training.11
For a given participant, up to 12 slides of colon, 6 slides of
skin, and 6 slides of SMG could be stained and interpreted,
but this varied based on presence of target tissue and staining
adequacy.
Statistical analysis
All statistical analyses were performed using SAS 9.4 (SAS
Institute Inc., Cary, NC).
Fisher exact, Wilcoxon rank-sum, and Kruskal-Wallis tests
were used to compare demographics and clinical charac-
teristics between the HC vs PD group and among PD
subgroups.
Linear regression was used to compare biofluid α-synuclein
measures across groups; all such models included age as a
covariate and specified biofluid α-synuclein rank values as the
outcome variable (with average ranks assigned in the event
of tied values). Sensitivity and specificity of biofluid total
α-synuclein levels, as a test for both PD diagnosis (PD vs
HC) and disease severity (advanced vs early PD), were ex-
plored using cutoff values derived from receiver operating
characteristic (ROC) curves. Optimal cutoffs were defined
by the point on the ROC curve that yielded the highest
Youden index (J = sensitivity + specificity − 1).18,19 ROC
curves were based on univariate logistic regression models
and estimates of the area under the ROC curve (AUC) were
also computed.
Peripheral tissue α-synuclein measures were compared both at
the participant and slide level. Subject-level differences were
assessed using exact Cochran-Mantel-Haenszel tests of the
association between group and α-synuclein positivity while
adjusting for age tertile (<59 vs 59–65 vs >65 years); where
applicable, group was defined as a nominal variable.
A participant was considered positive for pathologic α-synu-
clein for a given tissue when ≥1 slide was rated positive for
α-synuclein by ≥2 neuropathologists. In sensitivity analyses,
each slide examined was accounted for by using generalized
estimating equations to assess the effect of group on slide
positivity, while adjusting for age and correlation across slides
collected from the same individual (based on an exchangeable
correlation structure).
Exploratory analyses comparing patients with PD with posi-
tive vs negative tissue biopsies assessed categorical variables
using odds ratios and continuous variables based on differ-
ences in medians, with 95% confidence intervals (CIs) de-
rived using bootstrap resampling (n = 1,000 iterations).
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Sample size justification
S4 was estimated to have 80% power to detect a difference of
40% or more in CSF total α-synuclein between patients with
PD and HCs, with a sample size of 20 participants per group,
and assuming a significance level of 0.05. This was based on
data from the Parkinson’s Progression Markers Initiative, in
which mean baseline CSF levels of total α-synuclein were
1,845 ± 770 pg/mL.20 Due to the widely varying nature of
tissue acquisition and interpretation for tissue α-synuclein in
the literature, sample size calculations related to tissue were
not considered feasible for the study here.
Statistical analysis was 2-sided and assessed for significance at
the 5% level.
Data availability
De-identified data collected for this study will be available
online at braincommons.org by December 31, 2020. Data
requestors will need to sign a data access policy agreement via
the BRAIN Commons website (braincommons.org) to gain
access.
Results
Cohort characteristics
Eighty-two participants were enrolled. Eighty (59 PD, 21
HCs) contributed ≥2 tissue and ≥2 biofluid specimens and
are included in this analysis. Cohort characteristics are
shown in table 1. Male:female ratio was higher in PD vs HCs.
Themoderate PD subgroup was younger than the advanced PD
subgroup.
As expected, the PD group had higher scores on all measures of
motor and nonmotor manifestations of PD, and lower DAT
binding, compared to HC. There was a gradient of increasing
measures of motor severity with increasing disease duration
when comparing the early vs moderate vs advanced PD sub-
groups (table 1). DAT binding was lowest in the advanced
group, highest in the early group, and intermediate between the
2 in the moderate group.
α-Synuclein levels in biological fluids
Overall, total α-synuclein levels in CSFwere lower in PD vsHC
(table 2 and figure 1). Sensitivity and specificity for PD di-
agnosis for CSF α-synuclein was 87.0% and 63.2%, respectively,
and the AUC was 0.693 (95% CI 0.521–0.865). Total α-syn-
uclein levels in the other biofluids were not significantly dif-
ferent among the PD and HC groups (table 2) and their
sensitivity and specificity were therefore not considered.
Within the PD group, α-synuclein levels in serum were suc-
cessively higher in progressive disease stages (table 2 and
figures 1 and 2). In light of this finding, sensitivity, specificity,
and the AUC of total serum α-synuclein for distinguishing
between advanced vs early PD were explored and were 80.0%,
70.6%, and 0.776 (95% CI 0.619–0.934), respectively.
α-Synuclein in peripheral tissues
The mean number of slides per tissue type per diagnostic
group examined by each neuropathologist is shown in table
2. Images of typical slides rated as positive by neuropa-
thologists are shown in figure 2. Tissue biopsies for HCs
were negative in all but one case. The number of patients
with PD with positive staining for α-synuclein was 8/57 for
colon, 14/58 for skin, and 23/41 for SMG; this was signif-
icantly greater in PD vs HCs in skin and SMG (table 2 and
figure 1). The sensitivity of SMG α-synuclein staining for
PDdiagnosis (across disease stages)was 56.1%while specificity
was 92.9%. The sensitivity of skin α-synuclein staining for PD
diagnosis was 24.1% with a specificity of 100%. Skin was sig-
nificantly more likely to be positive in early and advanced PD
compared to HC, and SMG in moderate and advanced PD
compared to HC. When restricting analyses to the advanced
PD vsHC groups, sensitivity of SMG α-synuclein positivity was
78.6% and specificity was 92.9%; sensitivity of skin α-synuclein
positivity was 40.0% and specificity was 100%.
Among the 39 patients with PD with all 3 tissues sites
assessed, 14 had negative α-synuclein staining across all sites,
13 had 1 tissue positive, and 11 had 2 tissues positive, in-
cluding 8 with positive SMG and skin vs 3 with positive SMG
and colon. Only 1 patient, in the advanced PD group, had all 3
tissues positive; even in this case, only 1 of 2 skin sites was
positive.
Fourteen patients with PD had a positive skin slide, of whom
13 had adequate specimens obtained from both the para-
vertebral cervical region and thigh. Of those 13, 3 had only
thigh region positive, 7 had only paravertebral cervical region
positive, and 3 (2 early PD and 1 advanced PD) had positivity
in both regions.
There were no differences among the 3 PD subgroups in the
number of slides examined for any tissue type. The ad-
vanced PD group had the highest proportion of participants
positive for skin and SMG, but these differences were not
statistically significant (table 2). Participants with skin bi-
opsy positive for α-synuclein (n = 14) were older compared
to those without, as were those with positive SMG biopsy
(table 3). There were no significant differences in motor and
nonmotor measures in those with positive biopsy compared
to those without. However, of note, all SMG biopsies
obtained from patients with PD with pRBD yielded positive
α-synuclein staining. A significant relationship was found
between the odds of SMG positivity and mean striatal SBR,
adjusting for age and disease duration (odds ratio 0.11 [95%
CI 0.02–0.67]).
Within-subject α-synuclein across tissue
and biofluids
In the PD group, there were no significant differences in
α-synuclein levels in any biofluid among those with vs
without positive α-synuclein in skin or SMG tissue (table 4 and
figure 3).
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Table 1 Demographic and clinical characteristics across all groups in the Systemic Synuclein Sampling Study
Variable
Overall PD
(n = 59)
HCs
(n = 21)
p Value
(PD vs HC) Early PD (n = 18)
Moderate PD
(n = 20)
Advanced PD
(n = 21)
p Value
(PD subgroup)
Sex, n (%) 0.038 0.36
Male 41 (69) 9 (43) 14 (78) 15 (75) 12 (57)
Female 18 (31) 12 (57) 4 (22) 5 (25) 9 (43)
Age, y 0.41 0.008
Median (min, max) 62.7 (43.6, 85.5) 63.1 (51.3, 71.3) 62.1 (43.6, 85.5) 58.1 (49.4, 73.4) 67.8 (50.3, 84.9)
Mean ± SD 63.1 ± 8.6 61.0 ± 6.3 62.9 ± 9.9 59.3 ± 6.3 67.0 ± 7.9
Disease duration, moa NA <0.0001
Median (min, max) 42.1 (1.1, 245.3) NA 8.0 (1.1, 29.8) 41.2 (13.6, 70.5) 100.9 (45.1, 245.3)
Mean ± SD 57.7 ± 54.9 NA 10.6 ± 8.6 40.6 ± 16.1 114.5 ± 52.5
MDS-UPDRS part I <0.0001 0.21
Median (min, max) 7 (0, 24) 2 (0, 9) 7 (1, 24) 7 (0, 18) 9 (1, 21)
Mean ± SD 8.3 ± 5.1 2.9 ± 2.4 7.9 ± 5.6 7.1 ± 3.8 9.9 ± 5.4
MDS-UPDRS part II <0.0001 0.14
Median (min, max) 8 (0, 28) 0 (0, 4) 10 (0, 21) 7 (2, 15) 14 (2, 28)
Mean ± SD 9.5 ± 6.2 0.3 ± 0.9 8.5 ± 5.4 7.5 ± 3.8 12.2 ± 7.8
MDS-UPDRS part III (“off”)b <0.0001 0.003
Median (min, max) 25 (7, 56) 0 (0, 10) 18 (7, 40) 26 (7, 47) 31 (18, 56)
Mean ± SD 26.4 ± 11.9 1.1 ± 2.3 19.7 ± 9.4 26.3 ± 11.2 32.9 ± 11.5
Missing 5 0 0 3 2
MDS-UPDRS total score (“off”) <0.0001 0.013
Median (min, max) 41 (8, 90) 4 (0, 14) 33 (8, 74) 39 (15, 63) 48 (26, 90)
Mean ± SD 44.3 ± 19.1 4.3 ± 3.7 36.1 ± 16.6 40.8 ± 14.3 55.3 ± 20.6
Missing 5 0 0 3 2
MDS-UPDRS part IV NA 0.028
Median (min, max) 1 (0, 12) NA NA 0 (0, 11) 3 (0, 12)
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Table 1 Demographic and clinical characteristics across all groups in the Systemic Synuclein Sampling Study (continued)
Variable
Overall PD
(n = 59)
HCs
(n = 21)
p Value
(PD vs HC) Early PD (n = 18)
Moderate PD
(n = 20)
Advanced PD
(n = 21)
p Value
(PD subgroup)
Mean ± SD 2.7 ± 3.6 NA NA 1.5 ± 2.9 3.9 ± 3.9
Missing 18 NA NA 0 0
LEDD NA <0.0001
Median (min, max) 440 (0, 1700) NA 0 (0, 200) 420 (100, 750) 773 (100, 1700)
Mean ± SD 465 ± 429 NA 33 ± 59 426 ± 184 872 ± 395
Hoehn & Yahr (“off”),b n (%) <0.0001 <0.001
Stage 0 0 (0) 21 (100) 0 0 0
Stage 1 12 (22) 0 (0) 7 (39) 5 (29) 0 (0)
Stage 2 36 (67) 0 (0) 11 (61) 12 (71) 13 (68)
Stage 3 6 (11) 0 (0) 0 (0) 0 (0) 6 (32)
Missing 5 0 0 3 2
SCOPA-AUT total score <0.0001 0.10
Median (min, max) 12 (2, 33) 4 (0, 13) 12 (2, 33) 11 (4, 24) 15 (7, 23)
Mean ± SD 12.5 ± 5.5 4.9 ± 3.0 12.2 ± 7.1 11.5 ± 5.4 13.8 ± 3.8
UPSIT category, n (%) <0.0001 0.49
Normosmia 1 (2) 13 (62) 0 (0) 1 (5) 0 (0)
Hyposmia 28 (47) 7 (33) 9 (50) 11 (55) 8 (38)
Anosmia 30 (51) 1 (5) 9 (50) 8 (40) 13 (62)
Possible RBD, n (%) 0.058 0.021
No 48 (81) 21 (100) 18 (100) 16 (80) 14 (67)
Yes 11 (19) 0 (0) 0 (0) 4 (20) 7 (33)
MoCA 0.048 0.75
Median (min, max) 27 (21, 30) 28 (26, 30) 27 (21, 30) 28 (24, 30) 28 (21, 30)
Mean ± SD 27.0 ± 2.5 28.3 ± 1.2 27.0 ± 2.5 27.5 ± 1.8 26.5 ± 3.1
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Discussion
S4 measured α-synuclein in multiple biofluids and periph-
eral tissues within patients with PD of different disease
stages and compared to HC. The study was conducted with
rigorous standard operating procedures (SOPs) and train-
ing of involved neurologists, gastroenterologists, otolaryn-
gologists, and neuropathologists together with a robust
infrastructure providing core study functions, including
clinical site management, biorepository, statistical, and
neuropathologic expertise. This allowed centralized and
standardized specimen processing and analysis. We were
not able to replicate several previously reported findings
regarding high sensitivity of pathologic α-synuclein de-
posits in colon (up to 100%),21 skin (>90%),22 or SMG (up
to 100%).23–27 Also, we did not find a correlation between
intraindividual measures of total α-synuclein across the
various biofluids and tissues as we had hypothesized. De-
spite that, several important insights regarding the distri-
bution of α-synuclein have been garnered from this study:
(1) total CSF α-synuclein was significantly lower in the PD
compared to the HC group but the specificity of total CSF
α-synuclein for PD diagnosis is low; (2) serum α-synuclein
levels increase with disease severity, but do not distinguish
patients with PD from HC; (3) tissue positivity was sig-
nificantly more likely in PD vs HC in skin and SMG, and
was highly specific for PD, though with low sensitivity in
skin and SMG, at least in early PD23–25; (4) SMG tissue
positivity had relatively high sensitivity and specificity in
advanced PD and was related to DAT binding; and (5)
positive tissue was seen across all PD disease stages (ad-
vanced > early).
Similar to other studies,4,5 we found lower total CSF α-synu-
clein in the PD group compared to the HC group. How-
ever, total α-synuclein in the other biofluids was not
different in patients with PD vs HCs. The results are similar
to another recent multicenter study, using the same SOP
and analytical kits.8 This most likely relates to the “total”
nature of α-synuclein being quantified with currently
available assays and antibodies. While several assays for
total α-synuclein have been developed and proven to be
robust in several independent cohorts and one large round
robin study,7 they differ in the exact epitope bound by the
antibodies. No method ensures that full-length α-synuclein
is actually present, as opposed to N- or C-terminal-
truncated versions. These assays also have no specificity for
PD-specific pathologic forms of α-synuclein. Another
challenge in measurement of α-synuclein in biofluids, es-
pecially whole blood and its compartments, is the presence
of massive amounts of α-synuclein in red blood cells and the
influence of hemolysis on α-synuclein levels. It is likely
because of these limitations that total α-synuclein in CSF
performs only moderately well as a PD diagnostic bio-
marker, especially in smaller cohorts. Additional work,
using assays that are more sensitive, detect disease-specific
forms of α-synuclein, and/or different strains and aggregationTa
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Table 2 α-Synuclein measures in all peripheral tissue and biofluids across all groups
Variable
Overall PD
(n = 59) HCs (n = 21)
p Valuea
(PD vs HC)
Early PD
(n = 18)
Moderate PD
(n = 20)
Advanced PD
(n = 21)
p Valuea
(PD subgroup)
CSF α-Syn, pg/mL 0.009d 0.89
Median (min, max) 1,238 (667, 2,785) 1930 (625, 4,132) 1,230 (667, 2,686) 1,266 (732, 2,403) 1,275 (933, 2,785)
Mean ± SD 1,341 ± 478 1835 ± 832 1,293 ± 503 1,329 ± 474 1,387 ± 486
Missing/excludedb 13 2 4 6 3
Saliva α-Syn, pg/mL 0.35 0.097
Median (min, max) 52.7 (24.0, 208.6) 42.9 (24.0, 264.7) 44.0 (24.0, 114.4) 56.4 (24.0, 127.7) 57.5 (25.1, 208.6)
Mean ± SD 65.6 ± 42.1 64.4 ± 60.7 49.2 ± 25.4 63.1 ± 30.3 83.7 ± 57.9
Missing/excludedb 14 5 4 4 6
Whole blood α-Syn, pg/mL × 107 0.79 0.20
Median (min, max) 2.11 (1.64, 3.79) 2.07 (1.17, 3.01) 2.25 (1.64, 2.98) 2.04 (1.67, 3.06) 2.04 (1.64, 3.79)
Mean ± SD 2.20 ± 0.39 2.14 ± 0.46 2.25 ± 0.30 2.12 ± 0.33 2.24 ± 0.50
Plasma α-Syn, pg/mL × 104 0.71 0.44
Median (min, max) 8.25 (0.56, 26.73) 7.70 (0.94, 19.02) 8.25 (0.56, 13.09) 7.58 (2.28, 21.43) 9.84 (0.65, 26.73)
Mean ± SD 8.65 ± 5.17 8.07 ± 4.81 7.39 ± 3.84 8.37 ± 5.22 10.10 ± 6.08
Missing/excludedb 12 1 3 4 5
Plasma ratio (α-Syn/hemoglobinc) × 104 0.45 0.54
Median (min, max) 0.35 (0.02, 1.13) 0.28 (0.04, 0.75) 0.32 (0.02, 0.74) 0.34 (0.08, 0.73) 0.39 (0.02, 1.13)
Mean ± SD 0.37 ± 0.23 0.33 ± 0.21 0.33 ± 0.21 0.35 ± 0.20 0.43 ± 0.27
Missing/excludedb 12 1 3 4 5
Serum α-Syn, pg/mL 0.84 0.004
Median (min, max) 5,996 (1,589, 50,633) 4,817 (1,304, 89,724) 3,465 (1,589, 34,917) 6,332 (1926, 18,526) 9,995 (2,601, 50,633)
Mean ± SD 8,931 ± 9,033 14,893 ± 23,180 6,309 ± 8,228 7,161 ± 4,419 12,930 ± 11,733
Missing/excludedb 2 1 1 0 1
Serum ratio (α-Syn/hemoglobinc) 0.83 0.004
Median (min, max) 197 (58, 1,058) 168 (42, 980) 126 (58, 781) 197 (60, 514) 266 (105, 1,058)
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Table 2 α-Synuclein measures in all peripheral tissue and biofluids across all groups (continued)
Variable
Overall PD
(n = 59) HCs (n = 21)
p Valuea
(PD vs HC)
Early PD
(n = 18)
Moderate PD
(n = 20)
Advanced PD
(n = 21)
p Valuea
(PD subgroup)
Mean ± SD 246 ± 184 316 ± 302 185 ± 180 223 ± 128 322 ± 215
Missing/excludedb 2 1 1 0 1
Colon 0.18 0.77
Negative (0 positive slides), n (%) 49 (86) 21 (100) 13 (81) 19 (95) 17 (81)
Positive (≥1 positive slides), n (%) 8 (14) 0 (0) 3 (19) 1 (5) 4 (19)
Slides examined, mean ± SD 11.9 ± 0.6 11.7 ± 0.9 11.8 ± 0.8 12.0 ± 0.0 11.9 ± 0.7
No adequate colon obtained, n 2 0 2 0 0
Skin 0.030e,f 0.36
Negative (0 positive slides), n (%) 44 (76) 21 (100) 14 (78) 18 (90) 12 (60)
Positive (≥1 positive slides), n (%) 14 (24) 0 (0) 4 (22) 2 (10) 8 (40)
Slides examined, mean ± SD 5.9 ± 0.7 5.9 ± 0.7 5.7 ± 1.0 6.0 ± 0.0 6.2 ± 0.7
No adequate skin obtained, n 1 0 0 0 1
SMG 0.002g,h 0.51
Negative (0 positive slides), n (%) 18 (44) 13 (93) 9 (64) 6 (46) 3 (21)
Positive (≥1 positive slides), n (%) 23 (56) 1 (7) 5 (36) 7 (54) 11 (79)
Slides examined, mean ± SD 5.1 ± 1.4 5.1 ± 1.4 4.9 ± 1.5 4.8 ± 1.5 5.6 ± 1.1
No adequate SMG obtained, n 18 7 4 7 7
Abbreviations: α-Syn = α-synuclein; HC = healthy control; PD = Parkinson disease; SMG = submandibular gland.
a All p values are adjusted for age.
b For details on exclusionary hemoglobin cutoff levels, see Methods.
c Plasma and serum hemoglobin measured in mg/dL.
d Early PD < HC, p = 0.032; moderate PD < HC, p = 0.041; advanced PD vs HC, p = 0.15.
e Early PD > HC, p = 0.044; moderate PD vs HC, p = 0.49; advanced PD > HC, p = 0.009.
f A sensitivity analysis adjusting for within-subject correlation across slides could not be fit because the HC group did not yield any positive skin slides.
g Early PD vs HC, p = 0.067; moderate PD > HC, p = 0.014; advanced PD > HC, p = 0.022.
h A sensitivity analysis of the effect of group (PD vs HC) on SMG positivity, while adjusting for age and within-subject correlation across slides, supported this conclusion (p = 0.012).
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Figure 1 Heat map depicting, by subgroup, the relative degree of α-synuclein (α-Syn) positivity
α-Syn positivity across (A) each tissue type, as defined by the number of positive slides; and (B) each biofluid, as defined using quartile scores. For CSF and
serum α-Syn, rank values in the lower quartile (i.e., the lowest 25% of values) were defined as most indicative of Parkinson disease (PD), whereas for saliva,
plasma, and whole blood (WB) α-Syn, rank values in the upper quartile (i.e., the highest 25% of values) were defined asmost indicative of PD. For each panel,
participants are sorted by subgroup in order from lowest-to-highest average tissue positivity; accordingly, each given columnacross the 2 panels corresponds
to the same participant. PC = paravertebral cervical; SMG = submandibular gland; T = thigh.
Figure 2 Photomicrographs of skin, colon, and submandibular gland immunohistochemically stained for pathologic
α-synuclein with the 5C12 monoclonal antibody-based method
Photomicrographs of skin (A–E), colon (F–J), and submandibular gland (K–O). All panels show immunoreactivity independently judged by at least 2 of 3 blinded
neuropathologists to represent specific positive staining of nerve fibers. Specific positive staining in skin was most often seen in dermal periarteriolar
locations (A, B) and within small intradermal nerve fascicles (C, D) and less often adjacent to sweat glands (E). Specific positive staining was present in the
lamina propria of the mucosa (F, G) but more often in submucosal nerve fibers (H–J), sometimes in periarteriolar locations (J). Specific positive staining in
submandibular gland was seen both in the glandular parenchyma (K, L) and stroma (M–O); in stroma, it was often localized to nerve fascicles (N, O). The
calibration bar in (A) serves for all panels.
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Table 3 Clinical characteristics of patients with Parkinson disease (PD) with negative vs positive skin or submandibular gland (SMG) biopsies
Variable
Skin biopsy SMG
α-Syn-negative patients
with PD (n = 44)
α-Syn-positive patients
with PD (n = 14) Estimate (95% CI)
α-Syn-negative patients
with PD (n = 18)
α-Syn-positive patients
with PD (n = 23) Estimate (95% CI)
Male sex, n (%) 29 (66) 11 (79) 1.90 (0.46 to 7.85)a 12 (67) 17 (74) 1.42 (0.37 to 5.47)a
Age, y
Median (min, max) 60.6 (43.6, 78.4) 67.1 (56.4, 85.5) 6.5 (0.3 to 12.6)b 59.8 (43.6, 75.4) 66.8 (50.5, 85.5) 7.0 (1.2 to 11.0)b
Mean ± SD 61.4 ± 7.9 68.0 ± 9.2 60.8 ± 8.2 66.7 ± 8.9
Disease duration, mo
Median (min, max) 37.8 (2.5, 186.3) 71.5 (1.1, 245.3) 33.7 (−13.6 to 86.1)b 18.6 (2.6, 186.3) 57.4 (4.8, 245.3) 38.8 (12.7 to 104.0)b
Mean ± SD 47.9 ± 45.3 80.7 ± 69.3 38.0 ± 50.9 81.0 ± 64.0
Dopaminergic therapy, n (%)
Yes 30 (68) 10 (71) 1.17 (0.31 to 4.37)a 9 (50) 18 (78) 3.60 (0.93 to 13.95)a
MDS-UPDRS part III (OFF)
Median (min, max) 23 (7, 46) 36 (9, 56) 13.0 (−6.0 to 23.0)b 22 (7, 47) 27 (8, 56) 5.0 (−6.5 to 16.0)b
Mean ± SD 23.9 ± 10.0 33.1 ± 14.6 23.3 ± 11.8 28.8 ± 11.8
Missing 4 1 0 1
MDS-UPDRS total score (“off”)
Median (min, max) 40 (8, 83) 57 (20, 90) 17.5 (−14.0 to 40.0)b 42 (8, 74) 44 (24, 90) 2.0 (−13.5 to 21.3)b
Mean ± SD 41.2 ± 16.6 53.6 ± 24.3 40.1 ± 18.2 47.5 ± 19.3
Missing 4 1 0 1
LEDD
Median (min, max) 350 (0, 1,608) 600 (0, 1,077) 250 (−250 to 501)b 155 (0, 950) 600 (0, 1700) 445 (40 to 670)b
Mean ± SD 417 ± 401 529 ± 401 281 ± 305 635 ± 521
Hoehn & Yahr (“off”), n (%)
Stage 2 or 3 28 (70) 13 (100) 11.84 (0.65 to 215.2)a,c 12 (67) 19 (86) 3.17 (0.66 to 15.11)a
Missing 4 1 0 1
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propensity are needed.28–31 For example, the measurement
of soluble oligomeric forms of α-synuclein may offer the
advantage of detecting the earliest pathologic changes oc-
curring in α-synuclein.32 “Seeding assays,” such as the real‐
time quaking‐induced conversion technique or protein
misfolding cyclic amplification that both capitalize on the
prion-like aggregation properties of α-synuclein also hold
great promise, as several studies show, independently and
robustly across different laboratories, high sensitivity and
specificity for PD diagnosis.33 In turn, more disease-specific
α-synuclein measures in biofluids may better correlate with
tissue α-synuclein, especially if combined with application of
seeding assays to peripheral tissue.34 This approach will be
tested in remaining S4 samples. As for differences in biofluid
α-synuclein in relationship to PD disease severity, we found
significant stage-wise differences in total α-synuclein in se-
rum, raising the possibility that serum α-synuclein may have
the potential as a marker of PD severity. However, serum
total α-synuclein did not distinguish the overall PD group
fromHCs, indicating that more accurate assays are needed in
this regard.
Regarding the utility of peripheral tissue α-synuclein immu-
nostaining as a PD biomarker, the sensitivity of α-synuclein
for PD diagnosis in the literature, using various methods, has
been variably estimated at 36%–100% in colon,21 80%35 to
>90%22 in skin, and 74%–100%23–27 in SMG. In the small
studies done to date, specificity of α-synuclein has generally
been high (>90%) for SMG and skin but variable for
colon.9,21,36 In S4, we found high specificity of both SMG and
skin α-synuclein positivity for PD diagnosis, confirming some
previous results.23,24,37 The prevalence of colon positivity was
exceedingly low, though.
Among all the tissues studied, SMG α-synuclein had the
highest sensitivity, though it remained only moderate at 56%.
This improved when restricting analyses to the advanced PD
group. The relatively low sensitivities for skin and SMG at
earlier disease stages could reflect inclusion of misdiagnosed
patients with parkinsonism due to the higher ratio, in S4, of
earlier PD disease stages relative to prior studies.23 While the
use of DAT SPECT makes misdiagnosis less likely,38 it does
not eliminate it especially among neurodegenerative parkin-
sonian syndromes.39
The infrequent occurrence of α-synuclein positivity in co-
lon, despite examination of twice the number of slides
compared to other tissues, suggests that, using current
immunohistologic methods, colon is not an attractive bio-
marker site for PD. This is in contrast to a study showing
high sensitivity of colon α-synuclein21; those results may
have stemmed from false-positive nonspecific staining, risk
of which is mitigated by improved staining protocols and
rigorous pathologist training, as used in a multicenter
blinded-panel study and by S4.9,11,40 Another possibility is
that the S4 colon biopsies did not sample sufficient nervous
structures within the superficial colon submucosa. WhileTa
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Table 4 α-Synuclein (α-Syn) values among the patients with Parkinson disease (PD) with negative vs positive skin or submandibular gland (SMG) biopsies
Variable
Skin biopsy SMG
α-Syn-negative patients
with PD (n = 44)
α-Syn-positive patients
with PD (n = 14)
Difference in
medians (95% CI)
α-Syn-negative patients
with PD (n = 18)
α-Syn-positive patients
with PD (n = 23)
Difference in medians
(95% CI)
CSF α-Syn, pg/mL
Median (min, max) 1,222 (667, 2,785) 1,157 (708, 2,686) −65 (−299 to 420) 1,222 (760, 1800) 1,291 (667, 2,785) 69 (−254 to 428)
Mean ± SD 1,338 ± 468 1,350 ± 545 1,237 ± 278 1,422 ± 640
Missing/excludeda 11 2 3 5
Saliva α-Syn, pg/mL
Median (min, max) 55.2 (24.0, 208.6) 42.8 (24.0, 116.1) −12.4 (−33.0 to 51.9) 47.2 (24.0, 118.4) 64.6 (24.0, 202.8) 17.4 (−7.8 to 67.0)
Mean ± SD 64.2 ± 37.0 54.9 ± 38.2 52.4 ± 26.8 78.4 ± 44.6
Missing/excludeda 8 6 3 4
Whole blood α-Syn, pg/mL × 107
Median (min, max) 2.12 (1.67, 3.79) 2.04 (1.64, 3.16) −0.08 (−0.23 to 0.23) 2.22 (1.67, 3.06) 2.06 (1.64, 3.16) −0.16 (−0.39 to 0.05)
Mean ± SD 2.22 ± 0.39 2.20 ± 0.42 2.24 ± 0.33 2.15 ± 0.38
Plasma α-Syn, pg/mL × 104
Median (min, max) 8.80 (0.56, 26.73) 7.11 (0.65, 11.59) −1.70 (−5.09 to 1.51) 9.10 (1.95, 13.32) 7.77 (0.65, 21.43) −1.33 (−4.37 to 3.02)
Mean ± SD 9.19 ± 5.53 6.87 ± 3.34 8.55 ± 3.63 8.66 ± 5.40
Missing/excludeda 8 3 5 4
Plasma ratio (α-Syn/hemoglobinb) × 104
Median (min, max) 0.35 (0.02, 1.13) 0.28 (0.02, 0.73) −0.07 (−0.18 to 0.08) 0.36 (0.09, 0.74) 0.31 (0.02, 0.78) −0.05 (−0.26 to 0.06)
Mean ± SD 0.39 ± 0.24 0.32 ± 0.18 0.40 ± 0.19 0.34 ± 0.20
Missing/excludeda 8 3 5 4
Serum α-Syn, pg/mL
Median (min, max) 4,874 (1,589, 50,633) 7,268 (1891, 24,460) 2,394 (−2037 to 9,178) 3,886 (1992, 30,089) 6,255 (1891, 50,633) 2,369 (−1,369 to 12,054)
Mean ± SD 8,559 ± 9,730 9,386 ± 6,754 5,984 ± 6,390 11,627 ± 12,169
Missing/excludeda 2 0 0 0
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only biopsies confirmed to contain colonic submucosa were
analyzed in S4, neuron-specific staining of colon tissue to
confirm presence of neuronal tissue elements was not
conducted. Deeper and thereby more invasive biopsies,
attempting to obtain greater amounts of colonic submucosa,
may increase yield, but with higher risk. Postbiopsy mi-
crodissection techniques warrant further study as a means of
improving sensitivity.41 Another point regards the distal
location of gastrointestinal biopsy chosen in S4: the sigmoid
colon was chosen because sigmoidoscopy is safe and re-
quires minimal preparation. However, there is a known
rostral-caudal gradient of α-synuclein immunoreactivity
across the gastrointestinal (GI) tract, with higher α-synu-
clein load in more proximal/oral areas.21,42,43 Recent data
point to the promising application of seeding assays also to
biopsies in more rostral GI regions, including the stomach, as
well as other rostral areas of the environment–brain interface,
such as the olfactory mucosa,34,44 to identify sensitive PD
biomarkers. Future multicenter studies that follow similar
rigorous methodology to S4 will be needed to replicate these
promising preliminary results.
With respect to skin, we found a lower prevalence of positive
skin biopsies in the S4 PD cohort as compared to other
studies.35,37,45–47 The high specificity of the S4 immunohisto-
chemical method,11 the neuropathologist training and blinding,
and consensus-based decision-making could have resulted in
fewer false-positives. The staining protocol in S4 included pre-
treatment with a protease prior to 5C12 antibody application.
Extensive prestudy testing evidenced this method optimized
specificity and reduced false-positive staining for non-
pathologic forms of α-synuclein. While the 5C12 protocol
chosen for S4 was also the most sensitive among multiple
tested protocols, it is possible that some methods used by
non-S4 groups may be more sensitive. A double-
immunostaining protocol for α-synuclein phosphorylated at
serine-129 had a 70%–100% sensitivity and 100% specificity
for PD diagnosis in small studies,35 and preliminary work to
replicate across sites has demonstrated high reproducibility
though lower sensitivity than in the single-center studies.47
Application of that and other antibodies with specific affinity
for toxic/pathogenic forms of α-synuclein, such as truncated
or aggregated forms, should be tested, and S4 provides a
robust biorepository for such work in the future. Another area
of promise that warrants investigation is the application of
seeding assays to tissue.34
S4 results suggest that tissue α-synuclein positivity (in SMG
and skin) is seen across all PD stages. We also noted a
relationship between presence of SMG α-synuclein and
lower DAT binding, a measure of striatonigral denervation.
However, the small sample sizes across disease stages limits
interpretation and studies in a larger number of subjects
and longitudinal studies are needed to further explore this
observation. The higher prevalence of positivity in the
advanced PD group argues against the idea that with long-
standing PD, loss of peripheral nerve fibers reduces theTa
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chances of detection of α-synuclein,48 at least in the regions
biopsied in S4. Our results do not support the hypothesis
that peripheral pathology begins before the affection of the
CNS in PD,49 but our study was not designed to test this
hypothesis: we did not include prodromal/at-risk subjects
and our early PD cohort was small. It is also possible that
the 5C12 monoclonal antibody is less sensitive to the
species of pathologic α-synuclein seen in early PD. This
needs to be tested in a larger and longitudinal cohort that
includes participants along a spectrum of increased risk for
PD, and again using assays that more accurately detect
pathologic forms of α-synuclein, especially in early PD.
As for the within-subject distribution of α-synuclein, while
the 2 tissue types most often demonstrating positivity
together were skin and SMG, only 31% of the PD cohort had
2 or more positive tissues. These findings suggest that in the
periphery, α-synuclein distribution is patchy rather than
diffuse. This will be an important consideration in inter-
preting future studies of peripheral tissue α-synuclein. Re-
garding the relationship between biofluid and tissue α-synuclein,
saliva α-synuclein was higher in those with positive SMG, but
this did not reach significance. Differences in the type of
α-synuclein detected in biofluids vs tissue may account for
the lack of correlations of α-synuclein biofluid levels–tissue
positivity within subjects.
S4 is amulticenter study with rigorousmethods across all stages
of specimen acquisition, processing, and interpretation, which
is a major strength. However, several study limitations warrant
Figure 3 Scatterplot of CSF α-synuclein (α-Syn) (pg/mL) vs saliva α-Syn (pg/mL) vs the ratio of serum α-Syn (pg/mL) to serum
hemoglobin (mg/dL) among patients with Parkinson disease (PD) with adequate specimens obtained for all 3
biofluids
All values were plotted on the log scale. Each point represents a single patient with PD, with different colors and symbols indicating disease stage and
submandibular gland (SMG) biopsy status.
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mention. The small sample size in the PD subgroups limits
power to detect differences and interpret the results. As dis-
cussed above, the assays used for biofluid α-synuclein detect
total α-synuclein, and not necessarily its pathologic forms. In
tissue, the usage of protease pretreatment successfully removes
nonpathologic forms of α-synuclein and also improves epitope
exposure in paraffin-embedded tissue. Without protease pre-
treatment, antibodies against total or unmodified α-synuclein
stain normal peripheral nervous tissue, making it difficult or
impossible to definitively identify α-synuclein pathology.
However, overly aggressive protease treatment may impact
staining sensitivity. Future work to identify more sensitive tis-
sue α-synuclein stains that also preserve high specificity is
needed.
Several conclusions can be drawn from S4. The safety and
feasibility of multisite, multicenter tissue and biofluid sam-
pling in PD has been demonstrated. Our biofluids work
emphasizes the need for α-synuclein assays that measure PD-
specific forms of α-synuclein. Even in CSF, where significant
differences in total α-synuclein between PD and HC were
found, there was still overlap among values (even after
eliminating high hemoglobin samples) in the 2 groups and
suboptimal sensitivity and specificity. While we found high
specificity for PD diagnosis for α-synuclein staining with the
5C12 antibody in skin and SMG, S4 fails to replicate the high
sensitivity reported in several small, single-center studies of
mostly advanced PD cases in colon, skin, and SMG α-syn-
uclein. Instead, S4 indicates that, with the method used,
α-synuclein in these tissues is not a sensitive biomarker for
PD diagnosis, at least in the early stages of PD, where ac-
curate diagnostic biomarkers are most critically needed. As
for the utility of tissue α-synuclein as a marker of disease
severity, we found that tissue positivity occurs in all disease
stages, and we report a novel finding of SMG positivity being
more likely with greater striatal denervation as measured by
DAT binding. This may indicate that SMG positivity could
be a marker of more severe disease, but this requires addi-
tional studies and replication. With the limitations of current
biofluid assays and tissue staining procedures, we also show a
diffuse distribution of α-synuclein across the body and across
disease stages, though without the hypothesized relationship
across sites and fluids or within individual participants, at
least in the small numbers of participants examined here.
Importantly, S4 also provides the research community with
samples of fluids and tissues (accessible via michaeljfox.org),
with which to assess promising new assays and stains. Ulti-
mately, understanding the distribution of α-synuclein in
biofluids and tissues will help advance development of PD
biomarkers and our understanding of PD pathology in-
cluding its progression.
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